NCT05837299

A Study of IMC008 for Advanced Solid Tumors

A Clinical Study on the Safety and Preliminary Efficacy of IMC008 in the Treatment of CLDN18.2- Positive Advanced Solid Tumors

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Changhai Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

An open label, multi-center, dose-escalating study to evaluate the safety and preliminary efficacy of IMC008 in CLDN18.2 positive advanced solid tumors.

Detailed description

This study is an open label, multi-center, dose-escalating clinical study to evaluate the safety and preliminary efficacy of IMC008 in the treatment of CLDN18.2 positive advanced solid tumors. DLTs observations will be performed 28 days after IMC008 administration. During the study, regular safety meetings will be held according to the progress of the study, and recommendations will be made on dose escalation, safety of subjects and possible study change.

Conditions

• Advanced Solid Tumor

Interventions

Type	Name	Description
DRUG	IMC008	allowing 10% dose error

Timeline

• Start date: 2023-04-02
• Primary completion: 2025-12-31
• Completion: 2026-03-31
• First posted: 2023-05-01
• Last updated: 2023-05-01

Locations

1 site across 1 country: China